PS
PeptideScholar

Content reviewed by clinical research staff

Last reviewed: March 2026Sources: PubMed, FDA, WADA Prohibited List

Evidence graded using the PeptideScholar A-D system

Selank

BHuman Studies

Synthetic tuftsin analog · 7 amino acids

Not FDA ApprovedWADA Banned

Selank is a synthetic peptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is approved in Russia as an anxiolytic and nootropic medication.

Mechanism of Action

Modulates GABA and serotonin neurotransmission. Inhibits enkephalin-degrading enzymes, increasing endogenous enkephalin levels. Enhances BDNF expression.

Benefits

  • Anxiolytic effects demonstrated in Russian clinical trials
  • Nootropic and cognitive-enhancing properties
  • Approved and marketed in Russia as a nasal spray
  • No sedation or addiction potential observed
Not Medical Advice — Research-Reported Information Only

This content is for informational purposes only and does not constitute medical advice.

Selank — Dosing in Published Research

Reported Routes: Intranasal, Subcutaneous injection
Russian approved dosing: 150-300 mcg intranasal 3 times daily for up to 14 days. Not FDA approved.

The dosing information above is sourced from published research literature and clinical trials. These are not recommendations. Individual responses vary. Always consult a healthcare provider before considering any peptide-based therapy.

Side Effects

  • Generally well-tolerated in Russian clinical studies
  • Mild fatigue reported rarely
  • Nasal irritation with intranasal use
  • Limited Western clinical data

Considering Peptide Research?

Selank is not FDA-approved. Always consult a licensed healthcare provider before considering any peptide.

Learn About Finding a Provider
Always Consult a Professional

Research & Evidence

AnimalFrontiers in Pharmacology, 2016

Selank affects expression of GABAergic genes

Selank modulated GABA neurotransmission gene expression, supporting anxiolytic mechanism of action

PMID: 26891755
RCTBulletin of Experimental Biology and Medicine, 2008

Anxiolytic properties of Selank

Selank showed anxiolytic activity comparable to benzodiazepines without sedation or muscle relaxation in clinical trials

PMID: 18577768

Compare Selank With

Selank vs Semax
Selank vs DSIP

References

  1. 1. Selank affects expression of GABAergic genes. Frontiers in Pharmacology, 2016. “Selank modulated GABA neurotransmission gene expression, supporting anxiolytic mechanism of action” [PMID: 26891755]
  2. 2. Anxiolytic properties of Selank. Bulletin of Experimental Biology and Medicine, 2008. “Selank showed anxiolytic activity comparable to benzodiazepines without sedation or muscle relaxation in clinical trials” [PMID: 18577768]

Recommended Resources

The Peptide Protocols Handbook

Evidence-based reference guide covering mechanisms, research, and clinical applications.

View on Amazon

Third-Party Peptide Testing

Independent lab analysis to verify peptide purity and authenticity.

Learn More

Links may be affiliate links. See our disclosure.

Medical Disclaimer

This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.

No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.

Get Peptide Research Updates

Weekly evidence summaries and regulatory alerts.

No spam. Unsubscribe anytime.